US 12,138,322 B2
Method of preventing the development of melanoma
Peter Novak, Sunny Isles Beach, FL (US); Max Temnik, Miami, FL (US); and Oleksandr Balakin, Dnepropetrovsk (UA)
Assigned to Vector Vitale IP LLC, North Miami Beach, FL (US)
Filed by Vector Vitale IP LLC, North Miami Beach, FL (US)
Filed on Mar. 19, 2024, as Appl. No. 18/610,095.
Application 18/610,095 is a continuation of application No. 18/232,013, filed on Aug. 9, 2023, granted, now 11,986,541.
Application 18/232,013 is a continuation of application No. 17/969,297, filed on Oct. 19, 2022, granted, now 11,730,835, issued on Aug. 22, 2023.
Application 17/969,297 is a continuation of application No. 16/692,584, filed on Nov. 22, 2019, granted, now 11,484,610, issued on Nov. 1, 2022.
Prior Publication US 2024/0216552 A1, Jul. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 51/04 (2006.01); A61K 31/164 (2006.01); A61K 33/30 (2006.01); A61P 35/00 (2006.01)
CPC A61K 51/0476 (2013.01) [A61K 31/164 (2013.01); A61K 33/30 (2013.01); A61P 35/00 (2018.01)] 8 Claims
 
1. A method of reducing melanoma tumor growth of a primary melanoma in a patient in need thereof, comprising suppressing tumor growth of the primary melanoma in said patient by administering a pharmaceutical composition comprising a therapeutically effective amount of 64Zne(Asp)2, wherein from 0.2 μg/kg patient weight/day to 2000 mg/kg patient weight/day of 64Zne(Asp)2 is administered to said patient and wherein the 64Zne(Asp)2 is at least 80% 64Zn.